降低移植患者的血压:通过网络元分析进行系统性审查
Patrizia Natale1,2,3, Suetonia C Palmer4, Allison Jaure1,5
1Sydney School of Public Health, The University of Sydney, New South Wales, Australia.
Journal of hypertension
|January 17, 2024
概括
降血压剂不会减少移植患者的移植损失. 对它们的比较益处和安全性的证据有限,影响治疗决策.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 高血压在移植接受者中很普遍 (50-90%).
- 高血压与心血管疾病和移植损失有关.
- 移植后高血压的最佳管理需要基于证据的指导.
研究的目的:
- 为了评估血压降低剂的比较益处和危害.
- 评估这些药物在功能移植的个体中.
主要方法:
- 随机对照试验 (RCT) 的系统审查和网络元分析.
- 在 MEDLINE,Embase 和 CENTRAL 搜索到 2023 年 10 月.
- 包括血压降低剂的RCT在移植接受者中≥2周.
主要成果:
- 分析了94项研究 (7547名成年人).
- 与安慰剂相比,没有任何药物表明降低了移植损失,不良事件撤销,死亡或心血管/结局.
- ангиотензин转化酶抑制剂和 ангиотензин受体阻断剂与通道阻断剂相比,增加了高卡莱米亚风险 (低确定性证据).
结论:
- 对于移植患者的降血压剂的证据基础是有限的.
- 目前的证据不足以有效指导治疗决策.
- 需要进一步的研究来澄清比较的好处和安全性.
相关概念视频
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Antihypertensive Drugs: Direct Renin Inhibitors
631
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
631
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645
Antihypertensive Drugs: Action of Diuretics
697
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
697
Blood Pressure
1.1K
Blood pressure (BP) is the pressure or force of blood exerted on the artery's walls as it circulates through the body. It is essential for maintaining blood flow throughout the body.
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432


